This trial studies the safety and effectiveness of an antibody, GEN1047, in treating cancer. Participants will get GEN1047 in two parts to assess safety, dose and preliminary activity.
- Bladder Cancer
- Head and Neck Cancer
- Non-Small Cell Lung Cancer
- Uterine Cancer
- Squamous Cell Carcinoma of the Lung
- Cervical Cancer
- Ovarian Cancer
- Bile Duct Cancer
- Breast Cancer
- Endometrial Cancer
7 Primary · 23 Secondary · Reporting Duration: Up to 5 years
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
500 Total Participants · 2 Treatment Groups
Primary Treatment: GEN1047 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this particular trial actively seeking participants?
"According to clinicaltrials.gov, the search for participants is still ongoing - this trial was initially advertised on December 13th 2021 and has been regularly updated ever since its inception on April 19th 2023." - Anonymous Online Contributor
What is the participant count of this experiment?
"Affirmative. Clinicaltrials.gov data confirms that this research project, which was originally posted on December 13th 2021 is actively recruiting participants. Five hundred patients need to be enrolled at 8 different medical centres." - Anonymous Online Contributor
How many research sites are undertaking this trial?
"8 clinical sites, located in Nashville, Pamplona and Paris amongst other cities, are running this trial. When considering participation, it is best to select the nearest location so as to reduce travel time." - Anonymous Online Contributor